Connect with a PJM translator
Font size
Contrast version
Monochrome version
Text version
Reset settings
Dr Robert Czarnomysy received a research grant for the implementation of a project entitled ‘Development of new 1,3-selenazol-2-one derivatives incorporated into self-emulsifying drug delivery systems as an innovative strategy for experimental cancer therapy’. Although the title of the project may sound complicated, its essence is simple and extremely important from the patients' point of view. It is about searching for new, more effective methods of cancer treatment that may improve the effects of therapy in the future.
One of the biggest problems in modern oncology is the resistance of tumours to treatment. Dr Robert Czarnomysy's project responds to this challenge by developing new anti-cancer compounds based on 1,3-selenazolo-2-one derivatives and combining them with modern drug delivery systems.
Seleniu
m, a microelement known for its strong antioxidant properties, plays a key role in the research. Selenium participates in the protective mechanisms of normal cells and, at the same time, can influence the processes regulating the growth and survival of cancer cells. Preliminary studies have shown that the selenium derivatives used in the project are characterised by high anti-cancer activity and, at the same time, lower toxicity to healthy cells.
An important element of the project will be the use of SEDDS (Self-Emulsifying Drug Delivery Systems) technology. These systems improve the solubility and absorption of active substances and facilitate their delivery to cancer cells. This makes it possible to increase the effectiveness of therapy while reducing side effects.
As part of the project, scientists will conduct a detailed analysis of the developed compounds, examine their mechanisms of action, and evaluate their pharmacokinetic properties and safety. The results obtained may open up a new direction in the design of anti-cancer drugs and contribute to the development of more effective and safer therapies for patients.
Funding awarded to MUB for this project: PLN 3,073,640.
Duration: 48 months
The project is administered by the Department of Development and Evaluation at MUB.
